Emerging Paradigms in Severe Asthma Management: Integrating Technology and Personalized Treatment
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 72
Special Issue Editors
Interests: clinical research; chronic obstructive pulmonary disease; clinical studies; lung diseases; spirometry; asthma management; airway obstruction; allergic diseases; asthma; lung
Special Issue Information
Dear Colleagues,
Severe uncontrolled asthma is defined as asthma that remains insufficiently controlled despite receiving intensive asthma treatment after asthma diagnosis has been confirmed and considering comorbidities that may mimic asthma. The prevalence of severe uncontrolled asthma is estimated at 5% of all asthma cases. However, these patients account for more than half of total asthma expenditure, including direct and indirect costs. In this context, biological drugs have emerged as a promising option to address severe asthma. These medications target the specific immune system mechanisms involved in bronchial inflammation, providing a more precise and effective approach. By targeting specific cytokines and immune cells, biologics can help reduce symptoms, improve lung function, and decrease the frequency of exacerbations in patients with severe asthma. Although this therapeutic approach represents a significant advance, ongoing research and personalization of treatments are essential to optimize outcomes for people with this difficult respiratory condition.
A key theme of this Special Issue is the role of technology, particularly artificial intelligence (AI), telemedicine, big data, and bioinformatics, in transforming asthma care. The integration of these technologies is reshaping the management of asthma, enhancing diagnostic precision, personalizing treatment plans, and improving patient outcomes.
Overall, we aim for this Special Issue to serve as a comprehensive resource for clinicians, researchers, and policymakers, providing a multi-dimensional perspective on the latest trends in severe asthma management, with a particular focus on the role of technology and personalized treatment approaches.
Dr. Rudolfo Álvarez-Sala-Walther
Dr. Santiago Quirce
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- asthma
- precision medicine
- new technologies
- artificial intelligence
- cardiovascular comorbidities
- biological treatment
- efficacy evaluation
